By proceeding, you agree to our Terms of Use and Privacy Policy.
Burning Rock's laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification.
16-17 November 2022
In the wake of new FDA guidance and exciting MRD partnership announcements between Grail & AstraZeneca, Amgen & Bristol Myers Squibb the liquid biopsy industry is experiencing a paradigm shift.
Event Ended
USA
Paid
Boston
22-23 June 2023
The Biomarker and Companion Diagnostics Conference, organized by MarketsandMarkets, is set to take place on the 22nd and 23rd of June 2023 in Boston, USA. The event aims to explore how next-generation technologies can be used to advance biomarker dru
21-22 August 2023
The 8th annual Liquid Biopsy for Disease Management: From Discovery to Clinical Use conference will review new liquid biopsies coming on the market that have increased sensitivity and are robust enough for clinical applications for measuring treatmen
Hybrid
Washington, DC
The point-of-care industry is poised for tremendous growth and is fueled by both the explosion of enabling technologies as well as the huge need for disruption in the medical sector as consumers demand flexibility and access to testing as well as fas
Development of companion diagnostics shows no signs of slowing down anytime soon. As the field continues to grow, it is critical that the surrounding landscape progresses with it. Partnerships between pharmaceutical and diagnostic companies can lead
22-23 August 2023
The increase in testing and demands of the COVID-19 pandemic has spurred tremendous innovation for infectious disease testing platforms that reduce time, cost, and offer greater access than ever before. At the 15th Annual Advanced Diagnostics for Inf
As diagnostics become increasingly complex, coverage and reimbursement come to the forefront of challenges that diagnostic companies face. Deep understanding of how policy is developed and implemented and how policy will change over time will provide
Current guidelines call for screening for only five types of cancer, and in each case for one type of cancer per screen. This means that there are no screening tests available for the majority of cancers, and far too often cancer is only detected onc
Within the last few years, we saw a seismic global shift in the acceptance and availability of point-of-care and home-based testing, bolstered by a heightened interest in and capability for decentralized processes. Healthcare systems and providers we
05-08 September 2023
Welcome to the 13th Annual World Clinical Biomarkers & CDx Summit, the highly anticipated gathering that brings together over 600 senior decision makers in the field of biomarkers and companion diagnostics (CDx). This industry-led meeting aims to acc